Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)
China flag China · Delayed Price · Currency is CNY
26.56
-0.24 (-0.90%)
Apr 9, 2026, 3:00 PM CST

SHA:600196 Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
65,76265,09559,74961,59286,922113,862
Market Cap Growth
8.92%8.95%-2.99%-29.14%-23.66%-9.48%
Enterprise Value
99,929101,09890,78489,228110,109134,998
Last Close Price
26.8026.4924.5624.4633.9546.54
PE Ratio
21.1019.3121.5725.8223.3024.08
Forward PE
18.12-21.1521.4919.3620.43
PS Ratio
1.581.561.461.491.982.92
PB Ratio
1.061.051.001.091.612.35
P/TBV Ratio
2.752.722.732.893.995.83
P/FCF Ratio
85.9985.12894.58---
P/OCF Ratio
12.6112.4913.3518.0420.6128.92
PEG Ratio
-1.021.021.021.021.02
EV/Sales Ratio
2.402.432.212.152.513.46
EV/EBITDA Ratio
15.9817.1816.3422.9819.8732.27
EV/EBIT Ratio
35.8236.2330.5375.3432.1953.22
EV/FCF Ratio
130.66132.191359.25---
Debt / Equity Ratio
0.590.590.600.620.560.53
Debt / EBITDA Ratio
5.835.836.038.445.255.86
Debt / FCF Ratio
47.6347.63539.31---
Net Debt / Equity Ratio
0.340.340.330.340.240.23
Net Debt / EBITDA Ratio
3.583.583.585.012.352.60
Net Debt / FCF Ratio
27.5527.55297.96-10.12-7.79-10.53
Asset Turnover
0.350.350.360.380.440.44
Inventory Turnover
3.093.092.903.013.773.82
Quick Ratio
0.720.720.680.730.780.75
Current Ratio
0.930.930.921.001.061.04
Return on Equity (ROE)
6.98%6.98%6.03%5.23%7.70%10.55%
Return on Assets (ROA)
1.47%1.47%1.61%0.67%2.13%1.79%
Return on Invested Capital (ROIC)
2.78%2.85%3.21%1.47%4.67%3.56%
Return on Capital Employed (ROCE)
3.30%3.30%3.70%1.50%4.60%4.00%
Earnings Yield
5.13%5.18%4.64%3.87%4.29%4.15%
FCF Yield
1.16%1.18%0.11%-3.12%-1.92%-0.91%
Dividend Yield
1.46%1.47%1.30%1.10%1.24%1.20%
Payout Ratio
66.18%66.18%86.45%102.89%63.64%40.48%
Buyback Yield / Dilution
0.90%0.90%-0.02%-2.40%-1.74%-
Total Shareholder Return
2.36%2.38%1.28%-1.29%-0.50%1.20%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.